Management of low-risk prostate cancer

World Journal of Urology

Volumn 26, Issue 5, 2008, Pages 411-414

  Gardiner, Robert A ^a   Hamdy, Freddie C ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HUMAN; MALE; PROSTATE TUMOR; RISK FACTOR;

HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 53549130689     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0329-1     Document Type: Editorial

References (25)

1. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM et al (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248-1253
2. Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS 2/ ERG fusion messenger RNA is associated with aggressive prostate cancer. Cancer Res 66:8347-8351
3. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J et al (2007) TMPRSS 2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 31(6):882-888
4. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR et al (2007) TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596-4599. doi: 10.1038/sj.onc.1210237
5. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P et al (2008) Transatlantic Prostate Group. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27(3):253-263. doi: 10.1038/sj.onc.1210640
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
7. Stephenson AJ, Kattan MW (2006) Nomograms for prostate cancer. BJU Int 98:39-46. doi: 10.1111/j.1464-410X.2006.06173.x
8. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E et al (2002) Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664-1669. doi: 10.1016/ S0022-5347(05)65174-9
9. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ et al (2002) Scandinavian prostatic cancer group study number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347:790-796. doi: 10.1056/NEJMoa021483
10. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M (2007) Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 100:540-543. doi: 10.1111/j.1464-410X.2007.07009.x
11. Tsai YY, Thompson T, Frassica DA, DeWeese TL (2007) Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. Urology 70:111-116
12. Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M et al (2004) Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys 58:19-24. doi: 10.1016/S0360-3016(03)01433-0
13. Harnden P, Shelley MD, Clements H, Coles B, Tyndale-Biscoe RS, Naylor B et al (2007) The prognostic significance of perineural invasion in prostatic cancer biopsies: A systematic review. Cancer 109:13-24. doi: 10.1002/cncr.22388
14. Williams SG, Buyyounouski MK, Pickles T, Kestin L, Martinez A, Hanlon AL et al (2008) Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3, 264 men: Statistical significance without predictive performance. Int J Radiat Oncol Biol Phys 70:1169-1175. doi: 10.1016/j.ijrobp.2007.08.021
15. Weight CJ, Ciezki JP, Reddy CA, Zhou M, Klein EA (2006) Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 65:347-350. doi: 10.1016/j.ijrobp.2005.12.054
16. Skala M, Berry M, Duchesne G, Gogna K, Tai KH, Turner S et al (2004) Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer. Australas Radiol 48:493-501. doi: 10.1111/j.1440-1673.2004.01354.x
17. Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, Scrase C, Bossi A, Bolla M; EORTC radiation oncology group (2006) Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 79:259-269. doi: 10.1016/j.radonc.2006.05.012
18. Zeliadt SB, Potosky AL, Penson DF, Etzioni R (2006) Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 66:395-402. doi: 10.1016/ j.ijrobp.2006.04.048
19. Gregori A, Vieweg J, Dahm P, Paulson DF (2001) Comparison of ultrasound-guided biopsies and prostatectomy specimens: Predictive accuracy of Gleason score and tumor site. Urol Int 66:66-71. doi: 10.1159/000056573
20. Scales CD Jr, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL et al (2007) SEARCH Database Study Group. Predicting unilateral prostate cancer based on biopsy features: Implications for focal ablative therapy-results from the SEARCH database. J Urol 178:1249-1252. doi: 10.1016/j.juro.2007.05.151
21. Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ (2007) Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat 6:91-95
22. Villers A, McNeal JE, Freiha FS, Stamey TA (1992) Multiple cancers in the prostate: Morphologic features of clinically recognized versus. incidental tumors. Cancer 70:2312-2318 doi:10.1002/ 1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T
23. Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, Wilson RS, Kawata N, Sullivan H, Lucia MS, Werahera PN (2005) Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJUI 96:999-1004
24. Furuno T, Demura T, Kaneta T, Gotoda H, Muraoka S, Sato T et al (2004) Difference of cancer core distribution between first and repeat biopsy: in patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate 58:76-81. doi: 10.1002/pros.10298
25. Barzell WE, Melamed MR (2007) Appropriate patient selection in the focal treatment of prostate cancer: The role of transperineal 3-dimensional pathologic mapping of the prostate - a 4-year experience. Urology 70(6)(Suppl):27-35. doi: 10.1016/j.urology.2007.06.1126